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In vitro metabolism of selected bioactive compounds of 
Eurycoma longifolia root extract to identify suitable markers in 
doping control 
 
ABSTRACT 
Eurycoma longifolia Jack (Tongkat Ali, Simaroubaceae) is a medicinal plant endemic 
to South-East Asia. For centuries, different parts of the plant have been used as 
natural remedy to treat fever, hypertension or sexual insufficiency. Today, 
Eurycoma longifolia preparations are commercially available and advertised to 
enhance athletic performance and muscle strength. Several studies demonstrated a 
testosterone boosting effect that might be caused by the release of free testosterone 
from the sex hormone-binding globulin. To date, many phytochemical constituents of 
Eurycoma longifolia root extracts were identified and physiological effects have been 
examined, while studies on their biotransformation and monitoring are still lacking. 
Within this study, eurycomalide C, eurycomalactone, 5,6-dehydro-eurycomalactone, 
longilactone, 14,15β-dihydroklaieanone, 11-dehydroklaieanone, 
9-hydroxycanthin-6-one and 9-methoxycanthin-6-one isolated from E. longifolia root 
were incubated with liver microsomes. Respective metabolites were analyzed by 
liquid chromatography - tandem (high-resolution) mass spectrometry. The 
compounds were chosen based on their potential androgenic effects (estimated by 
in vitro-assays), their concentrations in plant extracts and presumptive metabolic 
pathways. Hydroxylated phase-I-metabolites were only observed for 
5,6-dehydro-eurycomalactone, 11-dehydroklaieanone, 9-hydroxycanthin-6-one and 
9-methoxycanthin-6-one. Moreover, an O-demethylated metabolite of 
9-methoxycanthin-6-one was found. Besides, the glucuronide of 
9-hydroxycanthin-6-one was detected after in vitro glucuronidation using liver 
microsomes. The in vitro generated metabolites were comparable to that detected in 
urine and serum after a single ingestion of either 9-methoxycanthin-6-one or an 
Eurycoma longifolia root extract. Hence, 9-methoxycanthin-6-one, its glucuronide 
and the glucuronide of its O-demethylated biotransformation product are proposed to 
be the most suitable targets for detection of its or Tongkat Ali application in urine and 
serum. 
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INTRODUCTION 
Herbs contain naturally occurring substances referred to as phytochemicals that may 
have nutritive value or medical importance and give rise to potential performance 
enhancement in sports. 
Eurycoma longifolia Jack is an evergreen shrub-tree endemic to South-East Asia 
belonging to the family of Simaroubaceae. It naturally grows in jungle slopes on 
sandy soils and reaches a height of up to 15 m. For centuries, preparations of 
several parts of Tongkat Ali (Eurycoma longifolia) have been used as natural remedy 
to treat fever, aches, hypertension or sexual dysfunctions and to improve general 
physical and mental strength [1]. Quassinoids, squalene-type triterpenes, tirucallane-
type triterpenes and canthin-6-one alkaloids have been determined as major 
phytochemical compounds of leaf, wood and root extracts of Eurycoma longifolia [2–
6]. It has been proven that the root extract has diverse effects including anti-malarial, 
anti-inflammatory and anti-rheumatic activities and that the extract is able to enhance 
muscle mass, libido and fertility [2–4,7–12]. Especially the androgenic potential of the 
root extracts of Eurycoma longifolia raised the interest of both scientists and athletes. 
Stimulation of the release of free testosterone from the sex hormone-binding globulin 
(SHBG) increases the level of bioavailable serum testosterone [12,13]. It has also been 
reported that an Eurycoma longifolia treatment may influence the hypothalamic–
pituitary–gonadal axis and hence increase the testosterone production [14]. 
Tongkat Ali applications could thereby compensate the age-dependent decline of 
testosterone and the related symptoms in men [15]. On the other hand, the 
testosterone boosting effect involves a high potential for abuse in sports when it 
comes to athletic performance, strength training and lower body fat [8,10,15]. 
Particularly in the bodybuilding scene, the use of Tongkat Ali crude extracts as 
dietary supplements is already widespread [1,16]. Interestingly, no impact on the 
urinary testosterone : epitestosterone (T:E) ratio, used in doping routine analysis for 
detection of exogenous testosterone abuse, was observed after a 6-week 
administration of an Eurycoma longifolia extract [17]. 
The intention of the present study was to investigate the metabolism of eight 
compounds isolated from Eurycoma longifolia root extract in order to identify 
metabolites as potential targets for doping analysis. Therefore, in vitro metabolism of 
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eurycomalide C, eurycomalactone, 5,6-dehydro-eurycomalactone, longilactone, 
14,15β-dihydroklaieanone, 11-dehydroklaieanone, 9-hydroxycanthin-6-one and 
9-methoxycanthin-6-one was performed and analyzed by mass spectrometry. 
Besides, the in vivo metabolism of 9-methoxycanthin-6-one as well as of an 
Eurycoma longifolia extract were investigated in different matrices after oral 
administration to a male volunteer. 
 
EXPERIMENTAL 
Chemicals and reagents 
Acetonitrile, acetic acid, ethanol and hydrochloric acid were purchased from 
Th. Geyer (Berlin, Germany). Ammonium acetate and formic acid (>98%) were 
purchased from Merck (Darmstadt, Germany). Dimethyl sulfoxide (DMSO) was 
supplied by Roth (Karlsruhe, Germany). Alamethicin, disodium phosphate, 
magnesium chloride, monopotassium phosphate, pooled liver microsomes from male 
Sprague Dawley rats, nicotinamide adenine dinucleotide phosphate (NADPH), 
uridine 5'-diphosphoglucuronic acid (UDPGA), t-butylmethylether (TBME) and XAD-2 
(100-200 µm particle size) were provided by Sigma-Aldrich (Taufkirchen, Germany). 
Ultra-pure water was prepared using the Milli-Q® Integral System (Merck Millipore, 
Darmstadt, Germany). β-Glucuronidase (from E.coli) was purchased from Roche 
(Mannheim, Germany) and testosterone-d3 was supplied by the National 
Measurement Institute (Pymble, Australia). EDTA S-monovettes® from Sarstedt 
(Numbrecht, Germany) were applied for blood collection. 
Test substances 
The extraction, isolation and characterization of the compounds from 
Eurycoma longifolia root, which were investigated in the present and other studies, 
have been described in detail previously [11]. The biotransformation of the 
quassinoids eurycomalide C (C1), eurycomalactone (C2), 5,6-dehydro-
eurycomalactone (C4), longilactone (C6), 14,15β-dihydroklaieanone (C7) and 
11-dehydroklaieanone (C8) as well as the alkaloids 9-hydroxycanthin-6-one (C14) 
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and 9-methoxycanthin-6-one (C15) was analyzed. All compounds were dissolved in 
DMSO (1 mM) and diluted in 100 mM phosphate buffer to a final concentration of 
10 µM for the liver microsome incubations. Tongkat Ali capsules (50:1, batch number 
1301009) were purchased from Vitalingo (Berlin, Germany). 
Metabolism of Eurycoma longifolia compounds by liver microsomes 
Pooled liver microsomes from different male Sprague Dawley rats of 8 to 10 weeks 
of age were quickly thawed at 37°C and kept on ice until ready to use. The 
incubation mixture for phase-I-metabolism contained 1 mg/mL microsomal protein, 
1 µM substrate and 50 mM phosphate buffer (pH 7.4). After 2 min pre-incubation at 
room temperature, the enzymatic reaction was initiated by adding 1 mM NADPH [18]. 
In vitro glucuronidation was performed as described previously with minor 
modifications [19]. Briefly, 9-hydroxycanthin-6-one, 1 mg/mL microsomal protein, 
50 µg/mL pore-forming peptide Alamethicin and 100 mM phosphate buffer (pH 7.4) 
were mixed and placed on ice for 15 min. After that, 1 mM MgCl2, 5 mM 
saccharolactone and the substrate (final concentration 50 µM) were added and 
incubated at 37°C for 3 min. The enzymatic reaction was initiated by adding UDPGA 
to a final concentration of 5 mM. 
Incubations were performed at 37°C and 350 rpm for 5, 10, 20, 40, 60, 120 and 
240 min. Control incubations were carried out without microsomes for 120 and 
240 min, respectively. The absence of background signals resulting from enzymes or 
reagents was confirmed. Reactions were terminated by placing the mixtures on ice. 
Protein precipitation was initiated by adding 1.6 mL of ice-cold acetonitrile/ethanol 
(1:1, v/v) to the phase-I-mixtures and 150 µl ice-cold acetonitrile to the phase-II-
reactions. The samples were centrifuged for 10 min at 12.000xg and 4°C. The 
residual organic phases were evaporated to dryness under nitrogen gas at 75°C and 
dissolved in the mobile phase. Samples were subjected to LC-MS/MS analysis. 
In vivo metabolism of 9-methoxycanthin-6-one 
Urine and serum samples (11 urine samples, 0-64 h and 9 serum samples, 0-40 h) 
were collected from a healthy male volunteer (self-administration by one of the 
authors, body mass index = 30) after oral ingestion of 5 mg pure 
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9-methoxycanthin-6-one (resolved in 40 % ethanol). Furthermore, the long-term 
detection of 9-methoxycanthin-6-one and its biotransformation products was 
examined in a hair sample 38 days after administration. 
Moreover, the recommended daily dose of 800 mg Eurycoma longifolia extract (two 
Tongkat Ali capsules) was ingested by the same healthy male volunteer (self-
administration by one of the authors). Urine was collected up to 48 h post-ingestion. 
Preparation of urine was carried out with (total fraction = conjugated and free 
fraction) and without hydrolysis (free fraction). Enzymatic hydrolysis was performed 
by incubation with β-glucuronidase for 1 h at 55°C. After addition of the internal 
standard (testosterone-d3) and solid-phase extraction of 2 mL urine (XAD-2, 100-
200 µm, Serva, Germany, pre-conditioned and washed by 5 mL water; elution by 
2.5 mL methanol), the eluate was evaporated and reconditioned by carbonate buffer 
(NaHCO3 + K2CO3, 1:1) and a liquid-liquid extraction was performed using TBME. 
Subsequently, the organic phase was removed under nitrogen gas at 75°C and the 
dried residues were re-dissolved in the mobile phase A (90% water, 
10% acetonitrile + 2 mmole/L ammonium acetate). Samples were subjected to LC-
MS/MS analysis. Serum samples underwent liquid-liquid extraction using TBME. For 
the quantification of the free fraction, the organic phase was removed under nitrogen 
gas at 75°C and the dried residues were re-dissolved in the mobile phase A (90% 
water, 10% acetonitrile + 2 mmole/L ammonium acetate). For the quantification of 
the glucuronidated fraction, the residual anorganic phase was enzymatically 
hydrolysed with β-glucuronidase and extracted using liquid-liquid extraction with 
TBME as described above. 
After cutting and weighing of the hair sample (50 mg), the internal standard 
(testosterone-d3) was added. The extraction was carried out with 2.5 mL methanol in 
an ultrasonic bath at 50°C for 4 hours. After evaporation of the extract under nitrogen 
stream at 60°C, acetonitrile and mobile phase A (90% water, 10% acetonitrile + 
2 mmol/L ammonium acetate) was added for reconstitution. Reconstituted samples 
were subjected to LC-MS/MS analysis. 
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Mass spectrometric analysis 
HPLC separations were performed using an Agilent 1200 Series HPLC system 
(Agilent Technologies, Boeblingen, Germany) equipped with a Kinetex C18 column 
(50 x 2.1 mm, 2.6 µm; Phenomenex, Aschaffenburg, Germany). The column 
temperature was set to 30°C, the sample volume injected was 10 µL (liver 
microsomal incubations), 5 µL (prepared serum and hair samples) or 0.5 µL 
(prepared urine samples). For the in vitro samples, the aqueous solvent (A) used for 
was 0.1% formic acid (v/v) in water/acetonitrile (95:5, v/v), and the organic phase (B) 
0.1% formic acid (v/v) in acetonitrile/water (95:5, v/v). After 3 min equilibration, the 
linear gradient started at 0% B and an initial flow rate of 300 µL/min. It was held for 
0.5 min and then increased to 100% B over 5 min at a flow rate of 500 µL/min. The 
flow rate was then set to 300 µL/min and the gradient was held for another 1.5 min 
before returning to 0% B over 1 min. For serum and urine, following a 5 min 
equilibration, the linear gradient started at 0% B and a flow rate of 200 µL/min which 
was held for 1 min and then increased to 100% B (10% water, 90% acetonitrile 
+2 mmole/L ammonium acetate) over 3 min at a flow rate of 200 µL/min. 
Mass spectrometric analyses of liver microsomal incubation samples were 
accomplished using a TripleTOF® 5600+ system (AB Sciex, Darmstadt, Germany) in 
positive electrospray ionization mode (resolution 16000). The ion source operated at 
500°C. Ion spray voltage and declustering potential were adjusted to 5500 V and 
90 V, respectively. Collision energy and collision energy spread were adjusted to 
35 eV and 15 eV, respectively. The curtain gas pressure was set to 40 psi, the ion 
source gas 1 and gas 2 pressures were set to 50 psi, respectively. Product-ion scan 
experiments were performed using collision-induced dissociation with nitrogen as 
collision gas. Mass spectra were obtained in positive product ion mode over a scan 
range m/z 100-800. A maximum of 5 product ion spectra per scan were recorded in 
information dependent acquisition mode. Data analysis was carried out using 
Analyst® TF 1.6 and PeakView 1.2 software (AB Sciex, Darmstadt, Germany). 
For the prepared serum, urine and hair samples, mass spectrometric analysis was 
accomplished using a Q-Trap 5500 mass spectrometer (AB Sciex, Darmstadt, 
Germany) with positive electrospray ionization. The ion source operated at 650°C, 
the ion spray voltage was adjusted to 5500 V. The multiple reaction monitoring 
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(MRM) transitions monitored are summarized in Table 1. Data analysis was carried 
out using Analyst® 1.5.1 and MultiQuant 3.0 software (AB Sciex, Darmstadt, 
Germany). 
 
RESULTS AND DISCUSSION 
Herbal supplements with presumptive performance enhancing effects are rather 
popular at least among recreational athletes [20]. The intention to include non-
approved compounds into doping analysis requires a proactive development of 
detection methods of potential doping substances. In the present study, we 
examined the biotransformation of several compounds of Eurycoma longifolia in vitro 
and used these respective metabolites as reference substances for an in vivo 
application. 
Metabolism of Eurycoma longifolia compounds by liver microsomes 
Figure 1a shows the time-dependent decrease of the parent compound C4 
(nomenclature according to [11]) during microsomal incubation whereas the amount of 
its hydroxylated form increased. A secondary hydroxylation as well as the 
hydrogenation of the parent compound was also observed even though at a lower 
intensity than the primary hydroxylation. The time-dependent decrease of the parent 
compound as well as the growing amount of phase-I-metabolites could be further 
demonstrated for other incubated test substances e.g. C8 (Figure 1b) and C14 
(Figure 1c). Both were metabolized to a hydroxylated form that accumulated over 
incubation time. High-resolution mass spectrometric data of C15, C14 and 
hydroxylated C14 were recorded (Figure 2a-c). While hydroxylation was the most 
important phase-I-reaction for C4, C8 and C14, C15 was rapidly O-demethylated to 
C14 (Figure 1d). Although hydroxylation products of both C15 and C14 were 
detectable in this mixture, their intensity was lower than the O-demethylation 
product. 
In addition to these four compounds, C1, C2, C6 and C7 were also tested regarding 
their in vitro phase-I-biotransformation by rat liver microsomes. However, no 
metabolites were detected. 
  
This article is protected by copyright. All rights reserved. 
The formation of possible biotransformation products was verified by their accurate 
mass and the mass shift from parent compound to metabolite (table 2). Figure 3 
illustrates the monitoring of C14 and its major hydroxyl metabolite by HRMS extra to 
corresponding product ion scans obtained after 240 min incubation. One peak was 
clearly detected at RT = 3.81 min corresponding to precursor ions at m/z = 237.0667 
(Figure 3a) for C14. Four other peaks were detected, whereas the major one was 
eluting at RT = 3.36 min (Figure 3b). These peaks correspond to precursor ions at 
m/z = 253.0611 for presumptive hydroxylation isomers of C14. 
In vitro phase-II-metabolism using liver microsomes yielded the glucuronide of C14 
and a decrease of the unchanged precursor as well as a temporal increase of the 
glucuronide (Figure 4) was observed. Figure 2d shows the high-resolution mass 
spectrum of the glucuronidated C14. 
In vivo metabolism of 9-methoxycanthin-6-one  
The in vivo biotransformation of the chosen key compound from the root extract of 
Eurycoma longifolia C15 was demonstrated. The aim of the application study was to 
examine the bioavailability of the parent compound and the presence of potential 
metabolites. Furthermore, the renal excretion of respective metabolites was 
examined to identify suitable markers for routine detection in doping control as urine 
is the main control matrix used in doping analysis [21]. 
The following target substances could thereby be verified: C15, its O-demethylation 
product C14, primary hydroxylated metabolites of C15 and C14, glucuronidated 
metabolites as well as a hydrogenation product of C14 presumably formed by 
reduction of its keto-group (data not shown). Figure 5 shows the time courses of the 
parent compound and the major metabolites in urine (Figure 5a) and serum 
(Figure 5b) samples. 
In urine, C15 was observed in the total fraction after hydrolysis comprising the 
unconjugated and the glucuronidated form. Moreover, its O-demethylated metabolite 
C14 was found to be mainly excreted in its glucuronide-conjugated form in the urine 
(Fig. 5a). In the serum, the parent compound C15 was only found in a free, 
unconjugated form, no C15-glucuronide was detected (Fig. 5b). In contrast, its 
metabolite C14 was only present as glucuronide. 
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Figure 6 exhibits typical LC-MS chromatograms of the free serum fraction 
(Figure 6a), total serum fraction (Figure 6b) and free urine fraction (Figure 6c) 
monitored at the MRM transitions specific for C14 and C15. The monitoring of 
hydroxylated urinary metabolites did not appear to be a suitable alternative due to 
their lower abundance. Additionally, sulfate metabolites were examined which did not 
provide any additional diagnostic relevance due to their limited sensitivity and 
reduced elimination time windows (data not shown). 
Hair serves as the typical specimen for long-term validation of unchanged precursor 
compounds [22]. Therefore, we examined a hair sample 38 days after administration 
of C15. As expected, we detected 2.5 pg/mg of unchanged C15, but no metabolites 
in the specimen (data not shown). Thus, the long-term detection of a C15 application 
is possible. 
Moreover, the urine analysis after ingestion of two commercially available 
Tongkat Ali capsules (corresponding to 800 mg Eurycoma longifolia root extract) 
showed detectable values of the parent compounds C14 and C15 up to 45 h post-
administration (data not shown). 
Resulting from the in vivo application study of C15, the parent molecule and the 
glucuronidated phase-I-metabolite C14 were the longest available compounds in the 
blood after the oral intake of 5 mg 9-methoxycanthin-6-one (Figure 5b). Other 
metabolites seemed to be rapidly excreted via urine. To verify the method’s 
compatibility with conventional LC-MS/MS routine procedures, respective 
fragmentation reactions were introduced into the screening for selected anabolic 
steroids, 2-agonists and others doping agents. Detection limits were mainly limited 
by the noise level of the hydrolyzed urinary matrix. The mean noise level related to 
C15 as examined in a sequence of 10 random blank samples corresponded to a 
LOD 0.06 ng/mL. A reproducibility of 14% was verified at a concentration level of 
0.5 ng/mL. The calibration curve was found to be linear (r=0.998) over the 
concentration range from 0.1-20 ng/mL (data not shown). 
Pointing out that these results are based on the metabolism by only one volunteer, 
the observations have to be proven by further investigations with more subjects. This 
is especially of interest with regard to the potential impact of age, gender, enzyme 
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polymorphisms or nutrition. The identification of the metabolites of 
Eurycoma longifolia and the knowledge on their time courses in urine and blood 
provides useful information on its oral bioavailability and permits the monitoring of its 
prevalence in sports. The classification of these compounds (i.e. their potential 
prohibition in sports) would require further studies on their biological mechanism of 
action and side effects. 
The time-dependent biotransformation of the parent compounds is mediated by 
enzymes of the cytochrome P450 (CYP) family. The use of rat liver microsomes was 
legitimate regarding the qualitative formation of several metabolites. Drug 
metabolism by rat and human microsomes only differs in terms of the activity of 
several CYP isoforms resulting in different conversation rates [23]. As the metabolites 
detected after ingestion of either C15 or Tongkat Ali were comparable to that 
generated in vitro, the usage of rat liver microsomes is reasonable. 
 
ONCLUSION 
This is the first study investigating the in vitro metabolism of eight 
Eurycoma longifolia compounds by liver microsome incubation. Phase-I-
biotransformation was only observed for 5,6-dehydro-eurycomalactone, 
11-dehydroklaieanone, 9-hydroxycanthin-6-one and 9-methoxycanthin-6-one. 
Moreover, 9-hydroxycanthin-6-one glucuronide was generated by in vitro 
glucuronidation using liver microsomes. The in vitro metabolites were comparable to 
those observed after ingestion of one single dose of either 9-methoxycanthin-6-one 
or Eurycoma longifolia root extract by one male volunteer. With regard to doping 
analysis, the proposed targets suitable for detection of Tongkat Ali application differ 
depending on the matrix. For urine, the glucuronides of 9-methoxycanthin-6-one and 
its metabolite 9-hydroxycanthin-6-one are proposed, while the unconjugated parent 
compound 9-methoxycanthin-6-one and the 9-hydroxycanthin-6-one glucuronide are 
proposed for detection in serum as matrix. 
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Table 1. MRM transitions for detection of 9-hydroxycanthin-6-one, 9-
methoxycanthin-6-one and their hydroxylated metabolites in human urine and serum. 
 
Alkaloid Metabolite MRM (m/z) DP (eV) CE (eV) 
9-hydroxycanthin-6-one 
(C14) 
 
Parent 237/209; 237/181 21 39;45 
Glucuronide 413/237; 413/209 141 20;45 
Hydroxylation 253/225; 253/197 21 39;45 
Hydroxy-Gluc 429/253 141 20 
9-methoxycanthin-6-one 
(C15) 
Parent 251/208; 251/180 141 45;55 
Hydroxylation 267/224; 267/196 141 45;55 
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Table 2. Accurate masses and proposed elemental compositions of relevant 
fragments of the 4 most abundant target compounds, i.e. C15 and corresponding 
C14 metabolites. 
 
Compound m/z (theoretical) Composition Error 
[ppm] 
C15 179.0604 C12H7N2+ 2.6 
parent compound 180.0682 C12H8N2+ 0.3 
  208.0631 C13H8N2O+ 0.9 
  236.0706 C15H10NO2+ 0.0 
  251.0815 C15H11N2O2+ 0.1 
C14 156.0444 C10H6NO+ 2.2 
parent compound 183.0553 C11H7N2O+ 0.6 
  191.0604 C13H7N2+ 1.3 
  208.0631 C13H8N2O+ 1.0 
  209.0709 C13H9N2O+ 3.4 
  237.0659 C14H9N2O2+ 2.9 
OH-C14 169.0760 C11H9N2+ 1.1 
hydroxy-
metabolite 
179.0577 C9H9NO3+ 12.6 
  207.0553 C13H7N2O+ 1.0 
  225.0659 C13H9N2O2+ 0.4 
  235.0502 C14H7N2O2+ 0.9 
  253.0608 C14H9N2O3+ 1.7 
OH-C14 237.0659 C14H9N2O2+ 4.4 
glucuronide    
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Figure 1. Time-dependent biotransformation of 5,6-dehydroeurycomalactone (C4, a), 
11-dehydroklaieanone (C8, b), 9-hydroxycanthin-6-one (C14, c), 9-methoxycanthin-6-one (C15, d) 
after liver microsome incubation. Control incubations were carried out without liver microsomes. 
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Figure 2. High-resolution product ion spectra of 9-methoxycanthin-6-one (C15, a), 
9-hydroxycanthin-6-one (C14, b), a C14-hydroxy-metabolite (c) and the corresponding glucuronide 
(d). Table 2 summarizes corresponding proposals of elemental compositions. 
 
 
 
 
 
 
 
a 
b 
c 
d 
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Figure 3. Extracted ion chromatogram of 9-hydroxycanthin-6-one (a, RT = 3.81 min) and its 
major hydroxylated metabolite (b, RT = 3.360 min) in positive ionization mode and product ion mass 
spectra after 240 min incubation. Detection of other metabolites at RT = 3.533 and 3.898 min indicate 
the presence of hydroxy-isomers of C14 (b). 
  
 
 
 
 
a 
b 
m/z = 237.0667 
m/z = 253.0611 
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Figure 4. Time course of phase-II-biotransformation of C14 incubation with liver microsomes. 
Control incubation was carried out without liver microsomes. 
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Figure 5. Time course of in vivo biotransformation of 9-methoxycanthin-6-one (C15). Urine 
concentration of total C15 (hydrolysed glucuronide + unconjugated fraction), total C14 (hydrolysed 
glucuronide + unconjugated C14) and the peak heights of the intact glucuronide of C14 (gluc-C14) (a) 
as well as serum concentration of free, unconjugated C15 (free-C15, no glucuronide-conjugated C15 
was detected) and glucuronidated C14 (gluc-C14) (b) are shown after ingestion of 5 mg C15 by a 
healthy male volunteer. 
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 Figure 6. Typical LC-selected reaction monitoring (MRM) chromatograms. Free serum fraction 
(a), total serum fraction (b) and free urine fraction (c) were monitored at the MRM transitions specific 
for C15 (251/208 Da, RT = 5.30 min) and C14 (237/209 Da, RT = 4.91 min). A hydroxylated 
metabolite of C14 (253/225 Da, RT = 4.76 min) was detectable in urine. 
C14 extracted after hydrolysis 
of the glucuronide serum 
fraction (1 h) 
+ MRM 237/209 Da 
c 
Hydroxy-C14 extracted  
from free urine fraction (40 h) 
+ MRM 253/225 Da 
C14 extracted  
from free urine fraction (40 h) 
+ MRM 237/209 Da 
a 
b 
C15 extracted from 
free serum fraction (1 h) 
+ MRM 251/208 Da 
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In vitro metabolism of Eurycoma longifolia root extracts to 
identify suitable markers in doping control 
Pia Bräuer, Patricia Anielski, Stefan Schwaiger, Hermann Stuppner, Thi Van Ahn 
Tran, Günter Vollmer, Oliver Zierau, Detlef Thieme, Annekathrin M. Keiler* 
 
 
Tongkat Ali is used as dietary supplement with anabolic effects among 
bodybuilders. In vitro and in vivo metabolism of Tongkat Ali compounds 
are described. LC-MS/MS analysis of parent compounds and 
metabolites identified target analytes suitable for doping routine analysis. 
 
 
